Cargando…
Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus
Alemtuzumab (Lemtrada(®)) is a humanized monoclonal antibody indicated for the treatment of adult patients with relapsing–remitting multiple sclerosis with active disease defined by clinical or imaging features. Alemtuzumab demonstrated superior efficacy over active comparator in both treatment naiv...
Autores principales: | Lambert, Catherine, Dubois, Benedicte, Dive, Dominique, Lysandropoulos, Andreas, Selleslag, Dominik, Vanopdenbosch, Ludo, Van Pesch, Vincent, Vanwijmeersch, Bart, Janssens, Ann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857274/ https://www.ncbi.nlm.nih.gov/pubmed/29380254 http://dx.doi.org/10.1007/s13760-018-0882-3 |
Ejemplares similares
-
Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus
por: Sprangers, Ben, et al.
Publicado: (2017) -
Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management
por: Decallonne, Brigitte, et al.
Publicado: (2018) -
A Belgian consensus on the definition of a treat‐to‐target outcome set in psoriasis management
por: Grine, L., et al.
Publicado: (2020) -
Consensus on targeted drug therapy for spondyloarthritis
por: Tian, Xinping, et al.
Publicado: (2023) -
Expert consensus on the assessment and treatment of chronic constipation in the elderly
por: Zheng, Songbai, et al.
Publicado: (2018)